Clinical Trial Update: Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose [Phase 3]

View source ↗

Summary

Phase 3 trial of rimonabant in abdominally obese patients with impaired fasting glucose was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Obesity | Phase 3 | Status: TERMINATED